Junshi Biosciences Chairman Continues Incremental Share Purchase Plan

An announcement from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) is now available.

Shanghai Junshi Biosciences has disclosed progress on a previously announced plan by chairman and controlling shareholder Xiong Jun to increase his holdings in the company’s A and H shares by at least RMB100 million over a 12‑month period starting 12 April 2025. The plan requires at least RMB50 million to be allocated to A shares and allows purchases via centralized bidding and block trades on the Shanghai and Hong Kong stock exchanges.

As of the latest update, Xiong has acquired 100,000 A shares through centralized bidding on the Shanghai Stock Exchange, representing 0.01% of the company’s total share capital and a total consideration of RMB3.84 million. The company emphasized that the share increase plan remains unfinished, Xiong intends to continue buying subject to market opportunities, and the outcome is still exposed to market and other unpredictable risks that could affect full execution.

The most recent analyst rating on (HK:1877) stock is a Hold with a HK$22.50 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.

More about Shanghai Junshi Biosciences Co., Ltd. Class H

Shanghai Junshi Biosciences Co., Ltd. is a PRC-incorporated biopharmaceutical company listed in both Shanghai and Hong Kong, trading under stock code 1877 in Hong Kong and 688180 on the SSE. The company is led by chairman and controlling shareholder Xiong Jun, with a board comprising executive, non-executive and independent non-executive directors overseeing its capital market activities.

Average Trading Volume: 3,197,016

Technical Sentiment Signal: Sell

Current Market Cap: HK$31.47B

See more insights into 1877 stock on TipRanks’ Stock Analysis page.